Liso-Cel Highly Active in Relapsed/Refractory DLBCL – OncLive
OncLive |
Liso-Cel Highly Active in Relapsed/Refractory DLBCL
OncLive Maloney: JCAR017 is a CAR T-cell product directed against CD19. This is in multicenter clinical trials in aggressive large B-cell lymphoma. The product is different from other CAR T cells since it is a subset population where patients have their cells … |
